surveillance. Preoperative knowledge of the probability of finding high-grade disease in the prostate specimen may also alter surgical technique or the decision to perform lymph node dissection. Chun et al. 18 , 19 developed 2 nomograms, one predicting Gleason
Search Results
Andrew K. Lee and Christopher L. Amling
Prajnan Das, Yixing Jiang, Jeffrey H. Lee, Manoop S. Bhutani, William A. Ross, Paul F. Mansfield, and Jaffer A. Ajani
Retrospective studies indicate that more extensive lymph node dissection improves outcomes over less extensive nodal dissection. 20 , 21 However, randomized trials comparing patients undergoing D1 lymphadenectomy (dissection of perigastric lymph nodes) with
Robert J. Motzer, Eric Jonasch, Neeraj Agarwal, Clair Beard, Sam Bhayani, Graeme B. Bolger, Sam S. Chang, Toni K. Choueiri, Brian A. Costello, Ithaar H. Derweesh, Shilpa Gupta, Steven L. Hancock, Jenny J. Kim, Timothy M. Kuzel, Elaine T. Lam, Clayton Lau, Ellis G. Levine, Daniel W. Lin, M. Dror Michaelson, Thomas Olencki, Roberto Pili, Elizabeth R. Plimack, Edward N. Rampersaud, Bruce G. Redman, Charles J. Ryan, Joel Sheinfeld, Brian Shuch, Kanishka Sircar, Brad Somer, Richard B. Wilder, Mary Dwyer, and Rashmi Kumar
lymph node dissection (RPLND) may be considered (category 2A). The other option, if resection is not feasible, is second-line chemotherapy (category 2A). Cisplatin-based combination chemotherapy is used for second-line treatment. 77 – 79 The regimens
Benjamin E. Greer, Wui-Jin Koh, Nadeem R. Abu-Rustum, Sachin M. Apte, Susana M. Campos, John Chan, Kathleen R. Cho, Larry Copeland, Marta Ann Crispens, Nefertiti DuPont, Patricia J. Eifel, David K. Gaffney, Warner K. Huh, Daniel S. Kapp, John R. Lurain III, Lainie Martin, Mark A. Morgan, Robert J. Morgan Jr., David Mutch, Steven W. Remmenga, R. Kevin Reynolds, William Small Jr., Nelson Teng, and Fidel A. Valea
alone with radical hysterectomy and lymph node dissection. 40 This study used adjuvant RT after surgery for women with surgical stage pT2b (which corresponds to FIGO stage IIB) or more extensive disease, less than 3 mm of uninvolved cervical stroma, and
Robert J. Motzer, Neeraj Agarwal, Clair Beard, Sam Bhayani, Graeme B. Bolger, Mark K. Buyyounouski, Michael A. Carducci, Sam S. Chang, Toni K. Choueiri, Shilpa Gupta, Steven L. Hancock, Gary R. Hudes, Eric Jonasch, Timothy M. Kuzel, Clayton Lau, Ellis G. Levine, Daniel W. Lin, Kim A. Margolin, M. Dror Michaelson, Thomas Olencki, Roberto Pili, Thomas W. Ratliff, Bruce G. Redman, Cary N. Robertson, Charles J. Ryan, Joel Sheinfeld, Jue Wang, and Richard B. Wilder
retroperitoneal lymph node dissection (RPLND), it is recommended between 3 to 6 months postsurgery and then as clinically indicated. 39 The follow-up of patients with stage IIB seminoma after chemotherapy is similar to follow-up after chemotherapy for patients
Christopher K. Bichakjian, Thomas Olencki, Murad Alam, James S. Andersen, Daniel Berg, Glen M. Bowen, Richard T. Cheney, Gregory A. Daniels, L. Frank Glass, Roy C. Grekin, Kenneth Grossman, Alan L. Ho, Karl D. Lewis, Daniel D. Lydiatt, William H. Morrison, Kishwer S. Nehal, Kelly C. Nelson, Paul Nghiem, Clifford S. Perlis, Ashok R. Shaha, Wade L. Thorstad, Malika Tuli, Marshall M. Urist, Timothy S. Wang, Andrew E. Werchniak, Sandra L. Wong, John A. Zic, Karin G. Hoffmann, Nicole R. McMillian, and Maria Ho
participating NCCN Member Institutions use the SLNB technique routinely for MCC, as they do for melanoma. The panel believes that identifying patients with positive microscopic nodal disease and then performing full lymph node dissections or RT maximizes the
Andrea Maurichi, Francesco Barretta, Roberto Patuzzo, Rosalba Miceli, Gianfranco Gallino, Ilaria Mattavelli, Consuelo Barbieri, Andrea Leva, Martina Angi, Francesco Baldo Lanza, Giuseppe Spadola, Mara Cossa, Francesco Nesa, Umberto Cortinovis, Laura Sala, Lorenza Di Guardo, Carolina Cimminiello, Michele Del Vecchio, Barbara Valeri, and Mario Santinami
. Nodal metastases are detected in 15% to 20% of patients with melanoma who undergo SN biopsy (SNB). 1 Until recently, most patients who were SN-positive were offered completion lymph node dissection (CLND) because evidence showed that it could improve
Stephen B. Edge
Krag DN Anderson SJ Julian TB . Sentinel-lymph-node resection compared with conventional axillary-lymph-node dissection in clinically node-negative patients with breast cancer: overall survival findings from the NSABP B-32 randomised phase 3 trial
Natalie Moryl, Nessa Coyle, Samuel Essandoh, and Paul Glare
52% had moderate to severe pain. 15 Factors associated with chronic pain included young age (18–39 years) and adjuvant RT, but not chemotherapy. Axillary lymph node dissection was associated with increased likelihood of pain compared with sentinel
Holly Dushkin and Massimo Cristofanilli
indicated as part of the systemic chemotherapy regimen. Mastectomy with axillary lymph node dissection is standard in patients with IBC who respond to preoperative chemotherapy. After surgery, postmastectomy radiation is recommended with adjuvant endocrine
